These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9600935)

  • 1. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.
    Zamble DB; Jacks T; Lippard SJ
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6163-8. PubMed ID: 9600935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
    Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells.
    Lutzker SG; Mathew R; Taller DR
    Oncogene; 2001 May; 20(23):2982-6. PubMed ID: 11420711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine methylation represses p53 activity in teratocarcinoma cancer cells.
    Zhu J; Dou Z; Sammons MA; Levine AJ; Berger SL
    Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9822-7. PubMed ID: 27535933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines.
    Burger H; Nooter K; Boersma AW; Kortland CJ; Stoter G
    Int J Cancer; 1997 Nov; 73(4):592-9. PubMed ID: 9389577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
    Eisenmann S; Voigt W; Müller T; Dempke W
    Anticancer Res; 2010 Nov; 30(11):4471-6. PubMed ID: 21115895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma.
    Kerley-Hamilton JS; Pike AM; Li N; DiRenzo J; Spinella MJ
    Oncogene; 2005 Sep; 24(40):6090-100. PubMed ID: 15940259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.
    Mao P; Hever MP; Niemaszyk LM; Haghkerdar JM; Yanco EG; Desai D; Beyrouthy MJ; Kerley-Hamilton JS; Freemantle SJ; Spinella MJ
    J Biol Chem; 2011 Jun; 286(22):19381-91. PubMed ID: 21489989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.
    di Pietro A; Koster R; Boersma-van Eck W; Dam WA; Mulder NH; Gietema JA; de Vries EG; de Jong S
    Cell Cycle; 2012 Dec; 11(24):4552-62. PubMed ID: 23165211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of protein kinase CK2 protein subunits and p53 in F9 teratocarcinoma cells in the absence and presence of cisplatin.
    Küpper M; Köster M; Schmidt-Spaniol I; Wagner-Gillen I; Issinger OG
    Cell Mol Biol Res; 1994; 40(5-6):587-92. PubMed ID: 7735333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and the ribosomal protein L5 participate in high molecular mass complex formation with protein kinase CK2 in murine teratocarcinoma cell line F9 after serum stimulation and cisplatin treatment.
    Guerra B; Issinger OG
    FEBS Lett; 1998 Aug; 434(1-2):115-20. PubMed ID: 9738462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
    Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
    Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UV but not gamma irradiation accelerates p53-induced apoptosis of teratocarcinoma cells by repressing MDM2 transcription.
    Zeng X; Keller D; Wu L; Lu H
    Cancer Res; 2000 Nov; 60(21):6184-8. PubMed ID: 11085543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of instability of p34(cdc2) expression by treatment with cisplatin (CDDP) in mouse teratocarcinoma F9 cells.
    Doi T; Morita T; Wakabayashi N; Sumi T; Iwai SA; Amekawa S; Sakuda M; Nishimune Y
    Cancer Lett; 2002 Feb; 176(1):75-80. PubMed ID: 11790456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.
    Roubalová E; Kvardová V; Hrstka R; Borilová S; Michalová E; Dubská L; Müller P; Sova P; Vojtesek B
    Invest New Drugs; 2010 Aug; 28(4):445-53. PubMed ID: 19499188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
    Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.